Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapseMark J. Levis, B. Douglas Smith, Harry P. Erba et al.|Blood|2011Cited by 402
A Randomized, Open-Label Study of Lestaurtinib (CEP-701), an Oral FLT3 Inhibitor, Administered in Sequence with Chemotherapy in Patients with Relapsed AML Harboring FLT3 Activating Mutations: Clinical Response Correlates with Successful FLT3 Inhibition.Mark J. Levis, Donald Small, B. Douglas Smith et al.|Blood|2005Cited by 57
Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse.Mark J. Levis, B. Douglas Smith, Farhad Ravandi et al.|Blood|2009Cited by 32